Connect Biopharma to Present at H.C. Wainwright BioConnect Conference
Event summary
- Connect Biopharma will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 9:30 a.m. ET.
- The presentation will be webcast live and archived for 90 days on the company's investor relations website.
- Connect Biopharma is focused on treating inflammatory diseases, particularly asthma and COPD, with its lead candidate rademikibart.
- The company has an exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China, with potential milestone payments up to $110 million and tiered royalties.
The big picture
Connect Biopharma's participation in the H.C. Wainwright conference underscores its focus on investor engagement amid critical clinical development phases. The company's strategic partnership with Simcere Pharmaceutical highlights its push into the lucrative Greater China market, where demand for innovative treatments for inflammatory diseases is growing. The potential milestone payments and royalties from this deal could significantly impact its financial trajectory.
What we're watching
- Clinical Progress
- The pace at which Connect Biopharma advances its global clinical studies for rademikibart in treating asthma and COPD exacerbations.
- Market Strategy
- How the company leverages its partnership with Simcere Pharmaceutical to penetrate the Greater China market.
- Financial Performance
- Whether Connect Biopharma can achieve the remaining milestone payments and sustain royalty revenues from the Simcere agreement.
Related topics